Background: Pregnancy may not be ideal due to the persistent systemic inflammation linked to psoriasis, which raises the possibility of unfavorable results. Does psoriasis or exposure to systemic therapy for moderate-to-severe psoriasis have an impact on pregnancy outcomes? Objective: To report pregnancy outcomes observed in the women with moderate to severe psoriasis and actively taken therapies <30 before conceiving and during any of the trimester. Methods: This was a retrospective observational registry, based on illness, that assessed clinical results and long-term safety. Pregnancy outcomes data from 98 women who became pregnant during the research period were analyzed after data from 135 psoriasis-affected women between the ages of 18 and 45 were gathered. In particular, exposure to biologic therapy is documented for medications licensed to treat psoriasis in India, such as cyclosporine, methotrexate, in fliximab, and etanercept. Documentation was kept on birth outcomes, which included stillbirths, spontaneous abortions, elective terminations, and full-term or preterm deliveries, adverse events in the neonate, and congenital abnormalities. Results: For the therapy of their psoriasis disease, enrolled patients were using etanercept (n=30), infliximab (n=26), methotrexate (n=23), and cyclosporine (n=19). Out of the 98 pregnancies, 89 births (90.81%) were achieved, comprising of 2 stillbirths after receiving methotrexate and in fliximab separately, 4 spontaneous abortions, and 5 elective terminations. Patients treated with etanercept had a low birth rate followed by patients treated with methotrexate, in fliximab, and cyclosporine. Six out of the 89 infants had congenital abnormalities, and two had neonatal problems. Conclusion: Pregnancy results in this case have not changed from earlier reports. Overall, live birth rates and overall health outcomes were comparable to those of the general population; however, infants delivered to these women had greater rates of congenital anomalies and required longer and more intensive medical treatment. All studied drugs have overall similar pregnancy outcomes.